Agency for Science, Technology and Research

Vib Vzw

Katholieke Universiteit Leuven

Katholieke Universiteit Leuven, Ku Leuven R&d

Ernesto Guccione

Jean-Christophe Marine

Marco Bezzi

Keng Boon Dave Wee

The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.

Direct and selective inhibition of MDM4 for treatment of cancer

The present invention relates to antisense oligonucleotides for modulating the activity of PRDM15 and use thereof in the treatment of cancer. In particular, said antisense oligonucleotides are capable of inducing the skipping of an exon of a PRDM15 mRNA. The present invention also relates to a method for determining prognosis in a patient with cancer, or selecting a therapeutic strategy for a patient with cancer, by assessing the level of PRDM15 nucleic acid, protein or activity in a sample.

Method of treating cancer by antisense oligonucleotides targeting PRDM15

Growing community of inventors

Singapore, Singapore

Ernesto Guccione